Technical Analysis for NLNK - NewLink Genetics Corporation

Grade Last Price % Change Price Change
grade C 1.82 -4.21% -0.08
NLNK closed down 4.21 percent on Friday, September 20, 2019, on 52 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical NLNK trend table...

Date Alert Name Type % Chg
Golden Cross Bullish 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Walk Strength -4.21%
Pocket Pivot Bullish Swing Setup -7.14%
Volume Surge Other -7.14%
Upper Bollinger Band Walk Strength -7.14%
Wide Bands Range Expansion -7.14%
Overbought Stochastic Strength -7.14%
Upper Bollinger Band Touch Strength -7.14%
Upper Bollinger Band Walk Strength -4.71%

Older signals for NLNK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company's lead product candidate, HyperAcute Pancreas cancer immunotherapy, is being studied in two Phase III clinical trials in surgically-resected pancreatic cancer patients. It is also developing HyperAcute Lung, which is being studied in a multi-center randomized, controlled Phase IIB/III clinical trials for non-small cell lung cancer; HyperAcute Melanoma that is in Phase II clinical trials for the treatment of melanoma; and a HyperAcute Renal cell cancer immunotherapy, as well as HyperAcute prostate and HyperAcute breast product candidates. In addition, the company is developing Indoximod, a small-molecule, orally bioavailable product candidate, which is being evaluated for the treatment of metastatic solid tumors in two Phase IB/II clinical trials; Provenge Indoximod that is in Phase II clinical trials for the treatment of prostate cancer; Docetaxel Indoximod, which is in Phase II clinical trials for the treatment of metastatic breast cancer; HyperAcute immunotherapy plus Indoximod that is in Phase IIB clinical trials; and NLG-919 IDO Pathway Inhibitor Candidate, which is in Phase I clinical trials for the treatment of metastatic solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Immunotherapy Prostate Cancer Cancer Immunotherapy Non Small Cell Lung Cancer Cancer Treatment Melanoma Metastatic Breast Cancer Bemcentinib Cancer Vaccine Treatment Of Prostate Cancer Metastatic Solid Tumors Treatment Of Metastatic Breast Cancer Immunotherapeutic Products Immunotherapy Technology Treatment Of Melanoma
Is NLNK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.6
52 Week Low 1.28
Average Volume 322,372
200-Day Moving Average 1.6549
50-Day Moving Average 1.6564
20-Day Moving Average 1.7405
10-Day Moving Average 1.866
Average True Range 0.1198
ADX 23.4
+DI 26.7275
-DI 16.4133
Chandelier Exit (Long, 3 ATRs ) 1.7406
Chandelier Exit (Short, 3 ATRs ) 1.8894
Upper Bollinger Band 2.0222
Lower Bollinger Band 1.4588
Percent B (%b) 0.64
BandWidth 32.370009
MACD Line 0.0785
MACD Signal Line 0.0647
MACD Histogram 0.0138
Fundamentals Value
Market Cap 53.55 Million
Num Shares 29.4 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.79
Price-to-Sales 6.79
Price-to-Book 2.71
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.00
Resistance 3 (R3) 2.00 1.95 1.97
Resistance 2 (R2) 1.95 1.90 1.95 1.96
Resistance 1 (R1) 1.88 1.87 1.86 1.88 1.95
Pivot Point 1.83 1.83 1.81 1.83 1.83
Support 1 (S1) 1.76 1.78 1.74 1.76 1.69
Support 2 (S2) 1.71 1.75 1.71 1.68
Support 3 (S3) 1.64 1.71 1.67
Support 4 (S4) 1.64